Please assess the completion status of the following clinical trial:

Trial Title: Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older with diabetic macular edema (DME) diagnosis secondary to diabetes mellitus Type 1 or 2~* Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 23 in the study eye~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed inform consent~Exclusion Criteria:~* Any signs of high risk proliferative diabetic retinopathy in the study~* Previously-treated patients who are not responders to anti-VEGF~* Panretinal laser photocoagulation within 6 months and macular laser photocoagulation with 3 months of screening in the study eye~Note: Other inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): AXT107 0.1 mg/eye
- Mid Dose (Type: EXPERIMENTAL): AXT107 0.25 mg/eye
- High Dose (Type: EXPERIMENTAL): AXT107 0.5 mg/eye

Based on this trial design, predict the completion outcome and termination type (if applicable).